The Mechanism Difference: Single GLP-1 Agonist Versus Dual GIP/GLP-1
Both medicines belong to what the press commonly calls the GLP-1 drug class, but their mechanisms diverge at a meaningful pharmacological level. Semaglutide is a selective GLP-1 receptor agonist. It binds to and activates the glucagon-like peptide-1 receptor, which slows gastric emptying, reduces appetite signalling, and enhances insulin secretion in a glucose-dependent manner.
Tirzepatide is a dual agonist. It activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor — a second incretin hormone pathway that regulates energy balance and fat storage through distinct mechanisms. The GIP receptor also modulates fat cell metabolism in ways that GLP-1 agonism alone does not, which is one proposed explanation for tirzepatide's higher average weight-loss outcomes in head-to-head data.
Whether that dual mechanism translates to a universally superior clinical experience depends on the individual patient — a point the trial data supports but does not always emphasise clearly.
SURPASS vs SUSTAIN: What the Phase-3 Trials Actually Showed
The major phase-3 trial programmes for each medicine were designed by their respective manufacturers and were not designed as head-to-head comparisons, though some data allows indirect comparison. The SUSTAIN programme tested semaglutide (under the Ozempic brand name, initially for type 2 diabetes) across a range of comparators and doses. The STEP programme tested semaglutide at 2.4 mg weekly (the Wegovy weight-management dose) in participants with obesity but without diabetes, with STEP 1 reporting average weight loss of approximately 15% at 68 weeks.
The SURPASS programme tested tirzepatide across multiple doses and comparators in type 2 diabetes populations. The SURMOUNT programme (the weight-management equivalent) tested tirzepatide at 5 mg, 10 mg, and 15 mg weekly in participants with obesity. SURMOUNT-1 reported average weight reductions of approximately 16%, 21%, and 22% across those three doses at 72 weeks, substantially exceeding the STEP 1 figure.
A direct randomised comparison of the two medicines (the SURMOUNT-5 trial) has generated data showing tirzepatide producing greater average weight loss than semaglutide 2.4 mg in direct comparison. The detailed semaglutide versus tirzepatide evidence comparison covers this trial data with the methodological context needed to interpret it properly.
Weight Loss Outcomes: Absolute Numbers and Realistic Expectations
The average weight-loss figures from the major trials are the most frequently cited numbers in public coverage, and they are also the most frequently misapplied. Trial averages describe the central tendency of a distribution that ranges from minimal response to very large response. Individual outcomes within the trial populations varied considerably around those averages, and the average in a trial population may not reflect the outcome for a specific patient who differs in age, starting weight, metabolic profile, medication history, and adherence.
Contextualising trial numbers also requires attention to the duration of treatment. Weight-loss curves in both trial programmes showed continued decline through the full study period, meaning patients who complete less than a full titration course, or who cannot access the full range of doses, will have outcomes that fall short of headline figures.
Both medicines require maintenance: the trial extension data for semaglutide is clear that weight is largely regained after discontinuation, and tirzepatide extension data points in the same direction. The headline numbers are real within their context; they are not outcomes patients should expect automatically.
Side-Effect Profiles: Where They Overlap and Where They Diverge
Gastrointestinal side effects are the dominant adverse event category for both medicines and reflect their shared GLP-1 mechanism. Nausea, vomiting, diarrhoea, constipation, and delayed gastric emptying occur in a substantial proportion of patients initiating either medicine, and they are most pronounced during dose escalation. Both medicines are titrated slowly to mitigate this.
The divergence in side-effect profiles is more nuanced. Some analyses of the SURMOUNT and STEP trial data suggest that tirzepatide's GIP component may alter the balance between specific gastrointestinal symptoms — there are signals that nausea rates, while still significant, may be somewhat lower relative to the weight-loss effect compared to semaglutide at equivalent weight-loss doses. This is not definitive, and individual experience varies considerably.
Both medicines carry the same class warnings relating to thyroid C-cell tumour risk seen in rodent studies, a personal or family history of medullary thyroid carcinoma as a contraindication, and attention to pancreatitis symptoms. Neither should be initiated without proper clinical assessment.
UK Availability, NHS Status, and Private Cost Comparison in 2026
Both medicines are licensed in the UK. Semaglutide is available as Ozempic (for type 2 diabetes) and Wegovy (for weight management). Tirzepatide is available as Mounjaro (for both type 2 diabetes and weight management). For the full detail on access routes, the tirzepatide UK status and patient information resource covers the current NHS and private prescribing landscape.
NHS access to both follows NICE guidance thresholds, with weight-management prescriptions typically requiring BMI-plus-comorbidity criteria and often routing through specialist weight services. Private prescriptions for both are available through registered clinics, with Mounjaro at lower dose levels typically available at comparable monthly cost to Wegovy, though both escalate significantly at maintenance doses.
Supply availability has affected both medicines unevenly at different periods since their launch, and patients starting treatment should discuss supply resilience with their prescriber.
Which Patient Profiles Might Favour One Over the Other
Prescribing decisions should be made with a qualified clinician who knows the patient's full medical picture. That said, several factors recur in the clinical discussion around comparative patient suitability.
Patients with type 2 diabetes who require both glycaemic management and weight loss may find that both medicines serve that dual goal, and the prescribing choice will partly depend on prior medication history and national prescribing guidance. Patients with a history of specific gastrointestinal conditions may have considerations that affect which medicine's profile is more suitable.
For patients without diabetes whose primary goal is weight management, the average magnitude of weight loss in the trial data favours tirzepatide at higher doses — but tolerability, access, and individual response remain determinative, and there is a meaningful population of patients who respond better to semaglutide or tolerate it more comfortably.
Questions to Bring to Your Prescriber Before Choosing
A useful prescriber conversation before initiating either medicine should cover: current medical conditions and how each medicine's mechanism interacts with them; current medications and the drug interaction profile of each; realistic expectations around both benefit and side effects; what monitoring will be in place; what the plan is if supply is disrupted; and what the long-term strategy is for discontinuation or maintenance. Patients who arrive at that conversation with a working understanding of the mechanism differences are better placed to ask useful questions and to understand the answers.
